De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

NCT06557421 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Institut Paoli-Calmettes